Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Receives Average Recommendation of “Hold” from Brokerages

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) has earned a consensus recommendation of “Hold” from the seven brokerages that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and one has given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $1.3517.

Several equities analysts recently issued reports on the company. Guggenheim cut Adaptimmune Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 29th. HC Wainwright reaffirmed a “neutral” rating on shares of Adaptimmune Therapeutics in a research report on Tuesday, July 29th. Wall Street Zen assumed coverage on Adaptimmune Therapeutics in a research report on Friday, May 16th. They issued a “buy” rating on the stock. Barclays lowered their price objective on Adaptimmune Therapeutics from $1.00 to $0.46 and set an “underweight” rating on the stock in a research report on Wednesday, May 14th. Finally, Wells Fargo & Company lowered their price objective on Adaptimmune Therapeutics from $1.50 to $1.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 14th.

Adaptimmune Therapeutics Stock Performance

Shares of ADAP opened at $0.06 on Monday. The company has a quick ratio of 1.29, a current ratio of 1.52 and a debt-to-equity ratio of 4.24. The business’s 50 day moving average price is $0.21 and its 200-day moving average price is $0.31. Adaptimmune Therapeutics has a 52 week low of $0.06 and a 52 week high of $1.33. The stock has a market cap of $15.77 million, a P/E ratio of -0.09 and a beta of 2.18.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. Adaptimmune Therapeutics had a negative return on equity of 163.73% and a negative net margin of 260.82%. The firm had revenue of $13.68 million for the quarter, compared to analysts’ expectations of $11.04 million. Equities research analysts anticipate that Adaptimmune Therapeutics will post -0.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ADAP. Invesco Ltd. lifted its holdings in shares of Adaptimmune Therapeutics by 82.0% during the 4th quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 28,526 shares during the period. Two Sigma Advisers LP lifted its holdings in shares of Adaptimmune Therapeutics by 492.0% during the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 58,787 shares during the period. Two Sigma Investments LP lifted its holdings in shares of Adaptimmune Therapeutics by 33.5% during the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 19,146 shares during the period. LPL Financial LLC lifted its holdings in shares of Adaptimmune Therapeutics by 106.5% during the 4th quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 94,623 shares during the period. Finally, Jane Street Group LLC lifted its holdings in shares of Adaptimmune Therapeutics by 87.7% during the 4th quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company’s stock valued at $176,000 after buying an additional 152,780 shares during the period. 31.37% of the stock is owned by institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.